Search This Blog

Thursday, April 9, 2020

Biden adviser Emanuel: US should prep for coronavirus rules to last 18 months

Dr. Zeke Emanuel, an adviser to Democratic presidential candidate Joe Biden on the coronavirus, said this week that Americans could be dealing with strict social distancing measures to combat the coronavirus for 18 months and that the U.S. “will not be able to return to normalcy until we find a vaccine or effective medications.”
Emanuel, one of the architects of the Affordable Care Act, also known as ObamaCare, is on the Biden campaign’s “Public Health Advisory Committee,” which is set up to “provide science-based, expert advice regarding steps the campaign should take to minimize health risks for the candidate, staff, and supporters,” according to a March press release.
His comments are partially consistent with statements from the Trump administration’s medical advisors and federal government documents on the pandemic. But they seem to paint a more grim picture of the country’s ability to roll back shutdowns of businesses and public life in general that are aimed at reducing the spread of the virus, which causes the disease known as COVID-19.

“Realistically, COVID-19 will be here for the next 18 months or more. We will not be able to return to normalcy until we find a vaccine or effective medications,” Emanuel said Monday on MSNBC’s “Last Word with Lawrence O’Donnell.”
“I know that’s dreadful news to hear,” the Biden adviser continued. “How are people supposed to find work if this goes on in some form for a year and a half? Is all that economic pain worth trying to stop COVID-19? The truth is we have no choice. … We cannot return to normal until there’s a vaccine. Conferences, concerts, sporting events, religious services, dinner in a restaurant, none of that will resume until we find a vaccine, a treatment, or a cure.”
He added: “We need to prepare ourselves for this to last 18 months or so and for the toll that it will take.”
The stark warning from Emanuel seems to contrast with Tuesday night comments by Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and the face of the White House’s coronavirus response. He predicted that American students would be able to return to school this fall even if the virus is still lingering.

“I fully expect – though, I’m humble enough to know that I can’t accurately predict – that by the time we get to the fall that we will have this under control, enough that it certainly will not be the way it is now where people are shutting schools,” Fauci said.
Fauci said that with increased testing for coronavirus antibodies, doctors will be able to identify people who have caught the disease and now have a natural immunity to it, therefore showing how much herd immunity the U.S. as a whole has to the virus. Additionally, more widespread testing for the virus itself would allow health authorities to better “identify, to isolate, to contact trace” in a way that countries with more successful early responses to the coronavirus have been able to.
An internal government document planning the coronavirus response, which was first obtained by the New York Times, predicted that the “pandemic will last 18 months or longer and could include multiple waves of illness.”

Fauci has also said there could be further waves of the coronavirus, particularly this fall.
The difference between the suggestions from Emanuel and those of figures in the Trump administration is Emanuel appears to be warning of serious challenges, absent a vaccine or medication, with prudently relaxing current protocols that have Americans working from home, wearing masks in public and canceling sporting events and religious services. Emanuel’s comments differ particularly from those of President Trump himself, who previously suggested the U.S. could try to get its economy running again by Easter before reversing himself to extend the White House’s social distancing guidelines through April.
“If we prematurely end that physical distancing and the other measures keeping it at bay, deaths could skyrocket into the hundreds of thousands if not a million,” Emanuel said. “One thing I’ve learned as a cancer doctor is that it’s wrong to paint an overly rosy picture in order to maintain a patient’s hope. It’s wrong because it fails. It’s false.”

As of Wednesday morning, the United States had just under 400,000 total coronavirus cases and nearly 13,000 deaths because of the virus. New York state, the hardest-hit area of the country so far, has 140,386 total cases and has seen 5,489 deaths.
“The crisis is not going to go away in a few weeks or after the 30-day plan comes to an end,” Emanuel concluded. “Although COVID-19 is affecting us in different ways, we have to be up to it and fight together.”
https://www.foxnews.com/politics/biden-obamacare-architect-zeke-emanuel-says-u-s-should-prepare-ourselves-for-coronavirus-social-distancing-to-last-18-months

Vapotherm up on accelerated review status for Oxygen Assist Module

The FDA has granted Breakthrough Device Designation for Vapotherm’s (NYSE:VAPO) Oxygen Assist Module (OAM).
The designation, akin to Breakthrough Therapy status for a drug, provides for more intensive guidance on development by the FDA, the involvement of more senior agency personnel, the assignment of a case manager and priority review of the marketing application.
Vapotherm OAM is a module for use with most versions of Vapotherm’s Precision Flow systems.
Shares are up 10% premarket.
https://seekingalpha.com/news/3559591-vapotherm-up-10-premarket-on-accelerated-review-status-for-oxygen-assist-module

Mesoblast on go with study of remestemcel-L in COVID-19

Mesoblast’s (NASDAQ:MESO) remestemcel-L will be evaluated in a placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by COVID-19.
This Phase 2/3 trial will be conducted as a public-private partnership in collaboration with the Cardiothoracic Surgical Trials Network, established by the U.S. National Institutes of Health’s National Heart, Lung and Blood Institute as a flexible platform for conducting collaborative trials.
https://seekingalpha.com/news/3559604-mesoblast-on-go-study-of-remestemcel-l-in-covidminus-19

Pfizer identifies lead COVID-19 candidate

The WSJ reports that Pfizer (NYSE:PFE) has found a promising coronavirus treatment that works by blocking viral replication. It plans to start testing this summer.
Rheumatoid arthritis med Xeljanz (tofacitinib), a Janus kinase inhibitor, is another option. Testing in COVID-19 patients will start this week in Italy.
Also, it intends to publish research on whether one of its antibiotics benefits COVID-19 patients.
Clinical trials should launch this month evaluating a vaccine candidate that it is developing with Germany’s BioNTech SE (NASDAQ:BNTX).
https://seekingalpha.com/news/3559589-pfizer-identifies-lead-covidminus-19-candidate

Tiziana Life Sciences up 91% on inhalable treatment of COVID-19

Thinly traded nano cap Tiziana Life Sciences plc (NASDAQ:TLSA) rockets 91% premarket on average volume in reaction to its announcement that it has developed an investigational new technology that enables the direct delivery of IL-6-inhibiting monoclonal antibodies into the lungs via a handheld inhaler or nebulizer.
The company says the technology advances its IL-6 candidate TZLS-501 for the potential treatment of COVID-19, adding that it could be useful with other antibodies and drugs. A provisional patent application has been filed.
It acquired the candidate from Swiss biotech Novimmune in 2017.
IL-6 is a proinflammatory cytokine (protein) that is believed to play a key role in the development of severe lung damage in severely ill COVID-19 patients with acute respiratory distress syndrome.
https://seekingalpha.com/news/3559578-tiziana-life-sciences-up-91-on-inhalable-treatment-of-covidminus-19

Stocks look for another winning session

Global stocks continue to gain on hopes that the pandemic is nearing a peak and that a crude oil output deal will be struck.
In Asia, the Shanghai Composite Index rose 0.4%, Hong Kong’s Hang Seng Index was up 1.3%, South Korea’s Kospi gained 1.6% and Australia’s ASX rallied 3.5%. Japan’s Nikkei ended flat on the day after a dour appraisal from Bank of Japan Governor Haruhiko Kuroda on the economy.
Meanwhile, European stocks are breaking higher, led by Germany’s DAX up 2.1% and U.K.’s FTSE 100 1.9% higher.
U.S. stock futures are all pointing to modest gains at the moment.
https://seekingalpha.com/news/3559556-stocks-look-for-another-winning-session

Wednesday, April 8, 2020

51 recovered coronavirus patients test positive again in South Korea

At least 51 patients diagnosed as having fully recovered from the coronavirus in South Korea have tested positive a second time after leaving quarantine, according to officials.
The patients from Daegu all tested positive in a “relatively short time” after they were given the all-clear from their initial infections, the Korea Centers for Disease Control and Prevention (KCDC) said, according to the government-funded Yonhap News Agency.
A specialist team has been sent to conduct an epidemiological investigation in the city, which is the epicenter of the epidemic in South Korea, the agency says.
For now, the KCDC’s director-general, Jeong Eun-kyeong, believes it is likely the infection was re-activated after remaining dormant in the patients, as opposed to them being reinfected, the report said.
Either way, it strengthens fears that the contagion remains a hidden danger even after it appears to have gone — with whistleblowing Chinese doctors previously warning it is even deadlier the second time.
Doctors on the front lines in Wuhan — where the virus first originated — previously said as many as 10% of those assumed to have recovered had tested positive again. At least one patient — Li Liang, 36 — reportedly died from the disease after previously getting the all-clear.
Paul Hunter, an infectious diseases professor at the University of East Anglia, told MailOnline that the cases were far more likely to be “reactivations” — or even just a sign of current testing being flawed.
“Personally, I think the most likely explanation is that the clearance samples were false negative,” Hunter told the site.
https://nypost.com/2020/04/07/51-recovered-coronavirus-patients-test-positive-again-in-south-korea/